Genetic diagnostic tests, including whole genome sequencing, are already improving patient care. Gene expression profi ling in peripheral blood constitutes the basis for an FDA-approved, cost-eff ective heart transplant rejection risk test. Matthew Price (Scripps Clinic, USA) described the use of the rapid point of care CYP2C19 genotyping test to identify patients with cardiac stents who will benefi t from clopidogrel, and the use of gene expression signatures such as Corus TM CAD (CardioDX ® , Palo Alto, CA, USA) to detect coronary artery disease (CAD) 
Tumor sequencing enables better understanding and treatment of cancer
Many cancer-related genes have been identifi ed in largescale sequencing projects. Some of these, such as B-RAF and K-RAS mutations, now provide individualized prognostic information. Recent data support the stance that personalized tumor biomarkers can be used to monitor tumor progression, and early genomic changes may be detectable even before cancer develops. Elaine Mardis (Washington University, USA), using nextgeneration whole genome sequencing of tumors, has identifi ed similarities, yet many diff erences, between primary tumors and metastases at diff erent sites, suggesting separate clonal evolution. Similarly, Samuel Levy (STSI, USA) talked about the great value of exome sequencing and the importance of accounting for tumor heterogeneity; Levy presented preliminary data from a tumor mapping project in which biopsies were taken from multiple diff erent locations in a single tumor and nearby tissue, and sequences were determined. Daniel von Hoff (T-Gen, USA) presented cases of patients treated successfully at his institution with targeted therapies that were selected based on individual tumor sequencing.
Improved risk prediction and management of diabetes and heart disease
Recent advances have been shown to be cost-eff ective and clinically useful in the treatment of diabetes and heart disease. After identifying 16 new loci contributing to the pathogenesis of type 1 diabetes (T1D), the T1D Genetic Consortium is transitioning from genome-wide association studies to gene discovery, and following strategies such as dense SNP mapping using the ImmunoChip, targeted sequencing studies in regions and exons of interest, and functional evaluation of genes associated with T1D. Advances in the pharmacogenomics of type 2 diabetes include the identifi cation of TCFL2 variants as predictors of poor response to sulfonylurea treatment. Philippe Froguel (Imperial College, UK) discussed the cost-eff ectiveness of diagnostic whole genome sequencing and the improvements of quality of life for patients with monogenic forms of diabetes who can stop insulin treatment when correctly diagnosed by genomic testing. Stimulating advances in risk prediction have also been made in the fi eld of cardiology: by adding 9p21 and another seven genetic risk factors to traditional CAD risk factor models, the deCODE MI TM (deCODE Genetics, Iceland) test demonstrated increased sensitivity to predict myocardial infarction.
The public perception of medical genomics reveals promises and pitfalls
Th e 'Views from the Outside' session provided a variety of perspectives on the impact of genomic medicine. Keynote speaker Juan Enriquez (Excel Venture Management, USA) believes that the genomic medicine biotechnology industry has the potential to foster economic growth, similar to the information technology industry. However, as an investor, he expressed concern about the elevating costs and overly stringent standards for drug development, as these may limit investor participation. In the fi eld of direct-to-consumer testing, Cinnamon Bloss (STSI, USA) presented the results of her study of behavioral consequences of direct-to-consumer genome-wide profi ling, where no additional anxiety was detected after learning genetic risk information for multiple diseases. Melanie Swan (DIYGenomics, USA) revealed a truly revolutionary enterprise where consumers, armed with their own genotyping information from commercial platforms, design and conduct their research studies using her web-based DIYGenomics organization. Th is probably refl ects what Eric Topol (Director, STSI, USA) referred to as the 'democratization of American medicine' , as the explosion in technologies and social networking result in a transformation in healthcare and medical research. Amy Harmon (Th e New York Times, USA) presented a cautionary tale about a clinical trial of an agent targeting B-RAF mutated melanoma. Despite unprecedented success and evidence of response to this new targeted agent in nearly all patients in initial studies, a randomized clinical trial was initiated, in which half the patients were assigned to the recognized standard treatment, known to have poor effi cacy, and were not given the opportunity to try the new treatment option. Harmon made a case for the need for more open conversations about research and its ethical implications with the public and with patients. She encouraged the use of open-access publications.
The bright future of genomic medicine
Th e current price of sequencing a whole single genome was estimated to be approximately US$30,000, but this fi gure appears to be dropping rapidly. Several speakers predicted that the cost of analyzing the ever-expanding amount of genomic data and presenting it in a meaningful format to physicians and patients is likely to become greater than the cost of sequencing itself. Clearly, genomic medicine is already benefi ting many patients and our evolving tools are rapidly expanding its reach. Clinical applications in cancer, diabetes, heart disease and other conditions are improving patient care and our ongoing discoveries should facilitate further translational advances. At the same time, investigators need to be attentive to the needs of patients and communities, and improve communication with physicians and other individuals outside of our fi eld as we move forward.
